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Abstract:  
Introduction: Basic experiments suggest that telmisartan, is unique among angiotensin receptor blockers in 
which it has a role in neural injury, neuroinflammation, and cognitive function by activating peroxisome 
proliferator activating receptor gamma (PPAR-γ). The aim of the study is to investigate the potential effect of 
telmisartan on the hippocampal immunohistochemical markers of male rats' dementia model induced by 
streptozocin intracerebroventricularly (ICV).  Materials and methods: Hippocampal alterations was induced by 
administering streptozocin (3 mg/kg ICV) and concomitantly treated with telmisartan (3mg/kg p.o) for 4 weeks 
in wistar albino male rats. Biochemical parameters include MDA, GSH, TNF-α and IL-1β in brain tissue were 
estimated. In addition immunohistochemistry for detection of Glial fibrillary acidic protein (GFAP) and neuronal 
nitric oxide synthase (nNOS) expression were also estimated.Results: Administration of streptozocin(STZ) was 
significantly increased oxidative stress and neuroinflammation of the rat's brain. Concomitant used of telmisartan 
significantly attenuate oxidative stress and neuroinflammation. Conclusion: Telmisartan has beneficial effects 
against oxidative stress and neuroinflammation in brain tissue of rats submitted to STZ ICV. 
Keywords: Telmisartan, hippocampus, oxidative stress, inflammation. 
 
1. Introduction 
The hippocampus is an area of the brain that is involved in short and long term memory [1, 2]. The loss of 
neurons or axonal degeneration secondary to ischemia can result in deficits of the hippocampus spatial memory 
[3]. Prolonged circulatory deficits induce irreversible changes in the brain tissue inflicting the damage and death 
of neural cells [4]. Ischemia is primarily occurs as a result of oxygen and energy substrates loss, for example, 
glucose. In contrast to glucose, which has some alternatives, oxygen has no substitute as the final electron 
acceptor in the oxidative phosphorylation pathway, which is why its loss dramatically decreases ATP production 
and causes an electron leakage generating reactive oxygen species (ROS). Persisting glycolysis leads to 
intracellular acidification further impairing cell functions [5]. Many possible risk factors and pathological 
alterations have been used in the elaboration of in vitro and in vivo models of this alteration in rodents, including 
intracerebral infusion of streptozotocin (STZ) [6]. Telmisartan, a unique angiotensin receptor blocker (ARB) 
with peroxisome proliferators activated receptor gamma (PPAR-γ) stimulating activity, protects against 
cognitive decline partly because of PPAR-γ activation [7]. Activation of PPAR-γ protects rat hippocampal 
neurons against A beta-induced neurodegeneration, by preventing the excitotoxic rise in bulk-free Ca
2+
. In 
addition, activation of PPAR gamma results in the modulation of Wnt signaling components, including the 
inhibition of glycogen synthase kinase-3beta (GSK-3beta) and an increase of the cytoplasmic and nuclear beta-
catenin levels [8]. The current study was designed to investigate the effect of telmisartan on 
immunohistochemical markers in the hippocampus of male rats dementia model induced by 
intracerebroventricularly (ICV) infusion of streptozocin(STZ).  
 
2. Material and method 
Experimental protocol 
The study included 36 wistar albino male rats weighing (200-250 gm); they were obtained from the animal house 
of the College of Pharmacy/Al-Mustansiriya University. The animals were maintained at controlled temperature 
(25±2 ˚C) with light schedule 12-12 hour's light/dark cycles, allowed free access to water, and fed standard rat 
chow add libitum. Telmisartan tablets were provided by Boehringer Ingelheim pharmaceutical company, 
Germany, while streptozocin was provided by Abcam, UK. Animals were allocated randomly into 3 groups and 
treated as follows: 
Group 1: includes 12 rats received saline orally for 4 weeks and served as negative controls. Group 2: 
includes 12 rats injected 3 mg/kg as a single dose of streptozocin ICV followed by oral saline for 4 weeks, and 
served as positive control. Group 3: includes 12 rats injected 3 mg/kg streptozocin ICV as a single dose followed 
by oral dose of 3 mg/kg telmisartan for 4 weeks. At the end of treatment period, all rats were sacrificed under 
anesthesia by intraperitoneal injection of 100 mg/kg thiopental (24 hours after the last administration of 
telmisartan and saline). Craniotomies were performed to obtain brains for the assessment of tissue damage.  
Preparation of samples and analysis  
After sacrificing the animals, brains were excised from each animal immediately, and the hippocampus tissues 
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obtained according to a rat brain atlas, placed in 10% formalin buffer solution for 24 hours at room temperature, 
blotted with filter paper and accurately weighed, followed by dehydration step, by immersing it in a gradually 
increasing concentration of alcohol. Brain tissues were kept in xylene for one hour under a temperature of 60˚C, 
and then embedding it in paraffin wax. A rotary microtome was used to cut sections at 5 µm in thickness, which 
sequentially mounted onto microscope slides, and stained with hematoxylin and eosin [9].  
Preparation of tissue homogenates 
A 10% (w/v) brain tissue was prepared in phosphate buffer at 4˚C, using metal head tissue homogenizer which 
adjusted at set 3 for one minute. The homogenate was then centrifuged at 10,000 g for 15 minutes and the 
supernatant formed was used for the biochemical estimations. All samples were kept frozen at (-18˚C) unless 
analyzed immediately. 
Biochemical assays  
Brain tissue homogenate malondialdehyde (MDA) and glutathione (GSH) assay 
The product of lipid peroxidation malondialdehyde (MDA) level was measured in tissue homogenates depending 
on the formation of pink chromophor because of the reaction between (MDA) and thiobarbituric acid (TBA), 
which can be measured spectrophotometrically according to the method of Buege and Aust [10].  Glutathione 
(GSH) levels were determined according to the method of Elman [11], in which 0.5 ml of 4% sulphosalcylic acid 
was added to the equal volume of tissue homogenate for precipitation of protein. 
Estimation of TNF-α and IL-1β levels in brain tissue 
The quantification of TNF-α and IL-1β was completed with the help and instructions provided by Ray Biotech. 
Inc. Quantikine rat TNF-α, IL-1β immunoassay kits. The assays employ the sandwich enzyme immunoassay 
technique [12].  
Immunohistochemistry for detection of Glial fibrillary acidic protein (GFAP) and neuronal nitric oxide 
synthase (nNOS) expression in paraffin –embedded sections: 
 The sections were processed by using paraffin embedded blocks which were sectioned at 5 µm for detection 
GFAP and nNOS using a commercially available kit. The sections were positioned on a positively charged slide. 
They were deparafinized and rehydrated through a descending alcohol series followed by distilled water. The 
sections were incubated with sodium citrate buffer in humidity heat chamber for antigen retrieval. Subsequently, 
the endogenous peroxidase activity was inactivated with hydrogen peroxide. The non specific bindings were 
blocked with a protein blocking reagent. Slides were examined, after staining with eosin and hematoxylin. 
Scoring of GFAP expression was done for percentage of staining intensity per field as following (157):0 = none, 
1 =< 5%, 2 =5-25%, 3 = 25-75% and 4 =75-100% [13]. The immunostaining for neuronal nitric oxide synthase 
(nNOS) was graded in five classes according to the percentage of stained tissue [14]: 0= when the staining was 
absent, 1= when the percentage of stained tissue varied from 1%-25%, 2= when the percentage of stained tissue 
varied from 26%-50%, 3= when the percentage of stained tissue varied from 51%-75% and 4= when the 
percentage of stained tissue was superior to 75%.  
Statistical analysis  
The data were expressed as mean ± standard error of the mean (SEM) and statistically analyzed by using 
unpaired student t-test and analysis of variance (ANOVA). P-values less than 0.05 were considered significant 
for all data presented in the results.  
 
3. Results 
Effect of telmisartan on MDA and GSH levels in brain tissue of rats treated by STZ 
Administration of 3 mg/ kg STZ ICV resulted in a significant elevation (p˂ 0.05) of MDA level and a 
significant(p˂ 0.05)  reduction of GSH level in brain tissue of rats treated with saline for 4 weeks when 
compared with group one(table 1). Meanwhile, daily oral administration of telmisartan( 3mg/ kg) for 4 weeks 
resulted in a significant(p˂ 0.05)  reduction of MDA level and a significant(p˂ 0.05)  elevation of GSH level in 
brain tissue of rats in group 3 when compared with those animals in group 2, but still these  values are 
significantly(p˂ 0.05)  different when compared with values of group 1(table 1). 
Effect of telmisartan on TNF-α and IL-1β levels in brain tissue of rats treated by STZ 
A significant (p˂ 0.05) decrease in TNF-α and IL-1β were recorded in rats given a single dose of STZ ICV when 
compared with group 1, meanwhile group 3 in which oral administration of telmisartan(3 mg/kg) concomitantly 
after STZ ICV significantly(p˂ 0.05)  reduced TNF-α and IL-1β when compared with group 2, but still 
significantly higher (p˂ 0.05) when compared with group 1 (table 1).  
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Table 1: The effect of 3 mg/kg telmisartan on biochemical parameters in brain tissue homogenate of rats treated 
by STZ 
Treatment groups MDA 
nmol/gm tissue 
GSH 
µmol/gm tissue 
TNF-α 
pg/ gm tissue 
IL-1β 
pg/ gm tissue 
Normal saline group n= 12  
43.5± 1.88
a 
 
10.45±0.13
a 
 
11.96±0.98
 a
 
 
4.76±0.66
 a
 
STZ(3 mg/ kg) 
n= 12 
 
92.87±2.57
b 
 
4.82±0.37
 b
 
 
69.1±3.41
 b
 
 
26.32±1.49
 b
 
STZ(3 mg/ kg) + 
telmisartan(3mg/kg) 
n= 12 
 
57.62±3.05
c 
 
6.69±0.24
 c
 
 
31.27±3.27
 c
 
 
18.33±1.15
 c
 
Data were expressed as mean ± SEM; n= number of animals, values with non identical superscripts (a,b,c) 
within the brain tissue were considered significantly different(p˂0.05) 
Effects of telmisartan on glial  fibrillary acidic protein (GFAP) 
Analysis of data statistically revealed a significant difference (p<0.05) among the groups. Administration of STZ 
followed by saline for 4 weeks in group 2 showed a significant (p<0.05) elevation in GFAP when compared with 
group 1. Furthermore, concomitant use of telmisartan (3 mg/kg p.o) showed significant (p<0.05) reduction when 
compared with group 2 but still significantly elevated when compared with group 1(table 2 and figures 1, 2 and 
3).  
 
(Figure 1): Immunohistochemical staining for hippocampus expressions of GFAP marker in the group one 
(saline group). (Scale bar at left lower corner represents 15µm (400 x) 
 
 
(Figure 2): Immunohistochemical staining for hippocampus expressions of GFAP marker in the group 
administered 3mg/kg streptozocin. (scale bar at left lower corner represents 15µm(400x)) 
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(Figure 3): Immunohistochemical staining for hippocampus expressions of GFAP marker in the group 
administered 3mg/kg streptozocin with 3 mg/ kg telmisartan (Scale bar at left lower corner represents 15µm 
(400x)) 
 
(Table 2): The effect of 3 mg/kg telmisartan on GFAP in hippocampus of rats treated by STZ 
Treatment groups GFAP nNOS 
Normal saline group n= 12  
1.97±0.15
a 
 
1.87±0.22
a 
STZ(3 mg/ kg) 
n= 12 
 
4.12±0.21
b 
 
3.44±0.15
b 
STZ(3 mg/ kg) + 
telmisartan(3mg/kg) 
n= 12 
 
 
2.29±0.12
c 
 
1.92±0.8
a 
Data were expressed as mean ± SEM; n= number of animals, values with non identical superscripts 
(a,b,c) within the brain tissue were considered significantly different(p˂0.05) 
Effects of telmisartan on neuronal nitric oxide synthase (nNOS) in the hippocampus of rats treated by 
STZ 
Table 3 showed that nNOS was significantly (p<0.05) reduced after the administration of STZ ICV when 
compared with control group; however administration of telmisartan orally in a dose of 3mg/kg for 4 weeks was 
concerned with significant (p<0.05)   elevation in the level of nNOS when compared with STZ treated group, 
nevertheless that comparison with group 1 was not significantly different (p˃0.05) (table 2 and figures 4, 5, 6).  
 
Figure 4: Immunohistochemical staining for hippocampus expressions of nNOS marker in the control (Scale bar 
at left lower corner represents 15µm (400x)) 
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Figure 5: Immunohistochemical staining for hippocampus expressions of nNOS marker in STZ treated group 
(Scale bar at left lower corner represents 15µm (400x)) 
 
 
Figure 6: Immunohistochemical staining for hippocampus expressions of nNOS marker in STZ + telmisartan 
treated group (Scale bar at left lower corner represents 15µm (400x)) 
 
Discussion 
Streptozocin induced many possible risk factors and pathological alterations have been used in the elaboration of 
in vitro and in vivo models of dementia in rodents, including intracerebral infusion of streptozotocin (STZ) [14]. 
STZ ICV produced impairment in cognition which concerned with a significant increase in brain 
myeloperoxidase activity, AChE activity, nitrite/nitrate levels and TBARS levels along with depletion of GSH 
levels [15].  In the current study STZ ICV was associated with significant elevation of oxidative stress and 
neuroinflammatory mediators including TNF-α and IL-1β in brain tissue homogenates which are in line with the 
previous studies [16, 17]. STZ ICV in rats causes desensitization of insulin receptors (IRs) and biochemical 
changes similar to that of Alzheimer dementia or aged brain [18, 19]. In brain tissue insulin controls the 
breakdown of glucose via IRs in brain which yields acetyl coenzyme A (acetyl CoA), glutamate and adenosine 
triphosphate (ATP) which required for normal structure and function of neurons [20].  The main constituent of 
acetylcholine synthesis is acetyl CoA, in which acetylcholine plays a vital role in the learning and memory 
processes. Insulin receptors IRs are concerned with memory functions and may get alterations due to oxidative 
stress induced by STZ result in myelin damage and dementia [20]. In addition, it has been reported that ICV STZ, 
causes an increase in inflammation by up regulation of some genes in brain tissue especially those encoding 
neurotrophic factor, glial cell derived neurotrophic factor and integrin-alpha-M, in which these findings agreed 
with the current study which report that inflammatory mediators TNF-α and IL-1β are elevated in brain tissue by 
administration of STZ ICV [21]. Furthermore, the up regulation of inducible nitric oxide synthase (iNOS) and 
concomitant increase in oxidative stress with administering STZ ICV leading to the formation of peroxynitrite, a 
powerful pro-oxidant [22].  
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In the current study the administration of telmisartan concomitantly with STZ was concerned with a 
significant reduction in oxidative stress and neuro-inflammation when compared STZ treated group only, but 
still reported that 4 weeks of telmisartan treatment was not enough to improve the results near that of group one 
(negative control), except nNOS level in brain tissue which became non significant (p>0.05) different when 
compared with group one. Telmisartan attenuated the damage effect of ICV STZ, as well as the histopathalogical 
changes. It has been reported that rennin angiotensin aldosterone system (RAS) in the CNS may contribute to the 
disease process of CNS disorders including Alzheimer disease, probably via neuronal death and memory 
dysfunctions [23]. Previous studies and literatures reported that high levels of angiotensin II contribute to 
oxidative stress, neuroinflammation and inhibit acetylcholine release in rats and humans [24, 25, 26, and 
27].Furthermore, it has been reported that stimulation of RAS causes activation of inflammatory cytokines that 
concerned with neuroinflammation and incidence of dementia[28].Thus, administration of ARBs like telmisartan 
in the current study may reduce the inhibitory action on acetylcholine release and thereby increase acetylcholine 
concentration as well as reduce the activation of inflammatory cytokines, in which this agree with other  
previous studies[29, 30]. Previous studies have been reported that telmisartan has agonistic activity at 
peroxisome proliferator activated receptor gamma (PPAR-γ) [31, 32]. Agonistic effects at PPAR-γ exert a 
neuroprotective and antioxidant effects in ischemia and intracerebral hemorrhage, since deficiency of neuronal 
PPAR-γ has been reported with cerebral damage after cerebral ischemia [33, 34, 35 and 36]. In addition, studies 
have also demonstrated that agonistic effects at PPAR-γ are concerned with anti-inflammatory properties which 
are due to negative regulation of the expression of pro-inflammatory molecules such as IL-1b and TNF-α which 
are in line with the current study [37, 38].  PPAR-γ considered as a novel target to manage decline in cognition 
in patients with Alzheimer dementia via reducing spatial memory impairment, Aβ aggregates, Aβ oligomers, 
astrocytic and microglia activation [39].  
 
Conclusion  
According to the results of the current study and the pharmacological actions of telmisartan mentioned above, 
one can conclude that telmisartan provide beneficial effects by improving oxidative stress and 
neuroinflammation induced by STZ ICV in rats. 
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